Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290795 | 1.00 | TSHR (0.33) | TSHRMAPTALDH1A1HSD17B10LPL | |
| SCHEMBL22290523 | 0.84 | LPL (0.38) | TSHRMAPTALDH1A1HSD17B10LPL | |
| SCHEMBL22290522 | 0.84 | LPL (0.38) | TSHRMAPTALDH1A1HSD17B10LPL | |
| SCHEMBL17629331 | 0.81 | KDM4E (0.36) | MAPTALDH1A1HSD17B10 | |
| SCHEMBL1660361 | 0.80 | LPL (0.40) | LPLLIPG | |
| SCHEMBL14321412 | 0.77 | HSD17B10 (0.41) | TSHRMAPTALDH1A1HSD17B10LPL | |
| SCHEMBL14321414 | 0.77 | HSD17B10 (0.41) | TSHRMAPTALDH1A1HSD17B10LPL | |
| SCHEMBL23731971 | 0.76 | MAPT (0.47) | TSHRMAPTALDH1A1LPLLIPG | |
| SCHEMBL31717778 | 0.76 | MAPT (0.47) | TSHRMAPTALDH1A1LPLLIPG | |
| SCHEMBL18420894 | 0.76 | MAPT (0.47) | TSHRMAPTALDH1A1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | TSHR 4351/4885MAPT 2074/4885ALDH1A1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.